Literature DB >> 17353071

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.

Pershia Samadi1, Laurent Grégoire, Marc Morissette, Fréderic Calon, Abdallah Hadj Tahar, Mehdi Dridi, Nancy Belanger, Leonard T Meltzer, Paul J Bédard, Thérèse Di Paolo.   

Abstract

Modulation of excessive glutamatergic transmission within the basal ganglia is considered as an alternative approach to reduce l-Dopa-induced dyskinesias (LIDs) in Parkinson's disease (PD). In this study receptor binding autoradiography of [3H]MPEP, a metabotropic glutamate receptor 5 (mGluR5) selective radioligand, was used to investigate possible changes in mGluR5 in the basal ganglia of l-Dopa-treated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys having developed LIDs compared to animals in which LIDs was prevented by adjunct treatments. LIDs were associated with an increase of mGluR5 specific binding in the posterior putamen and pallidum (+41% and +56%) compared to controls. By contrast, prevention of dyskinesias was associated with an important decrease of mGluR5 specific binding in these areas (-37% and -48%) compared with dyskinetic animals. Moreover, an upregulation (+34%) of mGluR5 receptor binding was seen in the anterior caudate nucleus of saline treated MPTP monkeys. This study is the first to provide evidence that enhanced mGluR5 specific binding in the posterior putamen and pallidum may contribute to the pathogenesis of LIDs in PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353071     DOI: 10.1016/j.neurobiolaging.2007.02.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  39 in total

Review 1.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates.

Authors:  R Sanchez-Pernaute; J-Q Wang; D Kuruppu; L Cao; W Tueckmantel; A Kozikowski; O Isacson; A-L Brownell
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

3.  Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.

Authors:  N Yamamoto; J-J Soghomonian
Journal:  Neuroscience       Date:  2009-08-04       Impact factor: 3.590

Review 4.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

5.  Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice.

Authors:  Francesca Managò; Sebastien Lopez; Alberto Oliverio; Marianne Amalric; Andrea Mele; Elvira De Leonibus
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

Review 6.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

7.  Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop
Journal:  ACS Chem Neurosci       Date:  2013-04-01       Impact factor: 4.418

8.  Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.

Authors:  Jonathan W Dickerson; P Jeffrey Conn
Journal:  Neurodegener Dis Manag       Date:  2012-04-01

9.  Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.

Authors:  Daniella Rylander; Alessandra Recchia; Flora Mela; Andrzej Dekundy; Wojciech Danysz; M Angela Cenci
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

10.  Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.

Authors:  Andreas Gravius; Andrzej Dekundy; Jens Nagel; Lorenzo Morè; Małgorzata Pietraszek; Wojciech Danysz
Journal:  J Neural Transm (Vienna)       Date:  2008-08-09       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.